HRP20170880T1 - Sastavi za brtvljenje - Google Patents
Sastavi za brtvljenje Download PDFInfo
- Publication number
- HRP20170880T1 HRP20170880T1 HRP20170880TT HRP20170880T HRP20170880T1 HR P20170880 T1 HRP20170880 T1 HR P20170880T1 HR P20170880T T HRP20170880T T HR P20170880TT HR P20170880 T HRP20170880 T HR P20170880T HR P20170880 T1 HRP20170880 T1 HR P20170880T1
- Authority
- HR
- Croatia
- Prior art keywords
- combination according
- combination
- tissue factor
- protein
- fibrinogen
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 5
- 239000000565 sealant Substances 0.000 title 1
- 108010000499 Thromboplastin Proteins 0.000 claims 4
- 102000002262 Thromboplastin Human genes 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 108010049003 Fibrinogen Proteins 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 2
- 230000004988 N-glycosylation Effects 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- 238000007789 sealing Methods 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940106780 human fibrinogen Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960003766 thrombin (human) Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/12—Polypeptides, proteins or derivatives thereof, e.g. degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/12—Polypeptides, proteins or derivatives thereof, e.g. degradation products thereof
- A61L33/126—Fibrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Sealing Material Composition (AREA)
Claims (15)
1. Kombinacija koja sadrži lipidirani tkivni faktor, trombin i fibrinogen.
2. Kombinacija u skladu s patentnim zahtjevom 1, pri čemu najmanje jedno N-glikozilacijsko mjesto tkivnog faktora nije funkcionalno.
3. Kombinacija u skladu s bilo kojim od patentnih zahtjeva 1-2, pri čemu je navedeni tkivni faktor fuzijski protein koji sadrži prvi dio koji sadrži protein tkivnog faktora i drugi dio koji sadrži drugi peptid ili protein.
4. Kombinacija u skladu s patentnim zahtjevom 3, pri čemu je drugi dio oznaka.
5. Kombinacija u skladu s bilo kojim od patentnih zahtjeva 1-4, pri čemu fuzijski protein ima prvi dio koji sadrži zreli protein ljudskog tkivnog faktora s najmanje jednim od N-glikozilacijskih mjesta koje je nefunkcionalno i drugi dio koji sadrži His-oznaku.
6. Kombinacija u skladu s patentnim zahtjevom 5, pri čemu fuzijski protein odgovara SEQ ID NO:5.
7. Kombinacija u skladu s patentnim zahtjevom 6, pri čemu je lipidirani TF umetnut u mikrovezikulu.
8. Kombinacija u skladu s bilo kojim od patentnih zahtjeva 1-14, pri čemu je trombin ljudski trombin.
9. Kombinacija u skladu s bilo kojim od patentnih zahtjeva 1-15, pri čemu je fibrinogen ljudski fibrinogen.
10. Sastav za brtvljenje sadrži kombinaciju u skladu s bilo kojim od patentnih zahtjeva 1-9, i nosač materijala.
11. Farmaceutski sastav sadrži terapijski učinkovitu količinu kombinacije kako je definirana u bilo kojem od patentnih zahtjeva 1-9, zajedno s drugim odgovarajućim farmaceutski ili veterinarski prihvatljivim ekscipijensima i/ili nosačima.
12. Kombinacija u skladu s bilo kojim od patentnih zahtjeva 1-9 ili sastav u skladu s patentnim zahtjevom 10 za uporabu kao agens za brtvljenje.
13. Kombinacija u skladu s bilo kojim od patentnih zahtjeva 1-9 ili sastav u skladu s patentnim zahtjevom 10-11 za uporabu kao lijek.
14. Kombinacija u skladu s bilo kojim od patentnih zahtjeva 1-9 ili sastav u skladu s bilo kojim od patentnih zahtjeva 10-11 za uporabu u liječenju krvarenja.
15. Komplet sadrži kombinaciju definiranu u bilo kojem od patentnih zahtjeva 1-9 i aplikator koji omogućuje istovremenu primjenu svih sastavnica koje čine kombinaciju.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12198839.8A EP2745852A1 (en) | 2012-12-21 | 2012-12-21 | Sealant compositions |
| EP13821692.4A EP2934612B1 (en) | 2012-12-21 | 2013-12-20 | Sealant compositions |
| PCT/EP2013/077674 WO2014096354A1 (en) | 2012-12-21 | 2013-12-20 | Sealant compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170880T1 true HRP20170880T1 (hr) | 2017-08-25 |
Family
ID=47563088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170880TT HRP20170880T1 (hr) | 2012-12-21 | 2017-06-08 | Sastavi za brtvljenje |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160082145A1 (hr) |
| EP (2) | EP2745852A1 (hr) |
| JP (1) | JP6518591B2 (hr) |
| CN (1) | CN104955493A (hr) |
| AU (1) | AU2013366544B2 (hr) |
| BR (1) | BR112015014926B1 (hr) |
| CY (1) | CY1118938T1 (hr) |
| DK (1) | DK2934612T3 (hr) |
| ES (1) | ES2627053T3 (hr) |
| HR (1) | HRP20170880T1 (hr) |
| HU (1) | HUE034649T2 (hr) |
| LT (1) | LT2934612T (hr) |
| MX (1) | MX361222B (hr) |
| PL (1) | PL2934612T3 (hr) |
| PT (1) | PT2934612T (hr) |
| SI (1) | SI2934612T1 (hr) |
| WO (1) | WO2014096354A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109010906B (zh) * | 2018-08-16 | 2021-05-14 | 陈明远 | 一种促进术后伤口局部止血及促进术后创面上皮化的生物胶水及其工作方法 |
| US11666682B2 (en) * | 2020-08-31 | 2023-06-06 | Ethicon, Inc. | Method of stopping CSF leaks and apparatus therefor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0748215B1 (en) * | 1994-02-17 | 2003-05-28 | New York Blood Center, Inc. | Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use |
| EP0885020A1 (en) * | 1996-02-20 | 1998-12-23 | Cohesion Corporation | Tissue sealant compositions and methods of use thereof |
| WO1999018931A1 (en) * | 1997-10-10 | 1999-04-22 | University Of Virginia | Use of fibrin sealant to maintain hemostasis, lymphostasis and prevent local accumulation of body fluids |
| EP1749536A1 (en) * | 2005-08-03 | 2007-02-07 | Thrombotargets Europe, S.L. | Activated factor X stimulants as new antihemorrhagic agents for topical use |
| EP1939218A1 (en) * | 2006-12-29 | 2008-07-02 | Thrombotargets Europe, S.L. | Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof |
| EP2145695A1 (de) | 2008-07-14 | 2010-01-20 | Sika Technology AG | Vorrichtung zur Klebstoffapplikation |
| EP2380905A1 (en) | 2010-04-19 | 2011-10-26 | Thrombotargets Europe, S.L. | Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof |
-
2012
- 2012-12-21 EP EP12198839.8A patent/EP2745852A1/en not_active Withdrawn
-
2013
- 2013-12-20 LT LTEP13821692.4T patent/LT2934612T/lt unknown
- 2013-12-20 ES ES13821692.4T patent/ES2627053T3/es active Active
- 2013-12-20 HU HUE13821692A patent/HUE034649T2/hu unknown
- 2013-12-20 DK DK13821692.4T patent/DK2934612T3/en active
- 2013-12-20 MX MX2015007625A patent/MX361222B/es active IP Right Grant
- 2013-12-20 AU AU2013366544A patent/AU2013366544B2/en not_active Ceased
- 2013-12-20 WO PCT/EP2013/077674 patent/WO2014096354A1/en active Application Filing
- 2013-12-20 JP JP2015548630A patent/JP6518591B2/ja not_active Expired - Fee Related
- 2013-12-20 BR BR112015014926A patent/BR112015014926B1/pt not_active IP Right Cessation
- 2013-12-20 SI SI201330670T patent/SI2934612T1/sl unknown
- 2013-12-20 EP EP13821692.4A patent/EP2934612B1/en active Active
- 2013-12-20 PT PT138216924T patent/PT2934612T/pt unknown
- 2013-12-20 CN CN201380071345.XA patent/CN104955493A/zh active Pending
- 2013-12-20 US US14/653,862 patent/US20160082145A1/en not_active Abandoned
- 2013-12-20 PL PL13821692T patent/PL2934612T3/pl unknown
-
2017
- 2017-06-08 CY CY20171100597T patent/CY1118938T1/el unknown
- 2017-06-08 HR HRP20170880TT patent/HRP20170880T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2934612B1 (en) | 2017-03-15 |
| ES2627053T3 (es) | 2017-07-26 |
| MX361222B (es) | 2018-11-30 |
| CY1118938T1 (el) | 2018-01-10 |
| AU2013366544B2 (en) | 2017-05-25 |
| EP2745852A1 (en) | 2014-06-25 |
| MX2015007625A (es) | 2015-12-15 |
| BR112015014926B1 (pt) | 2020-01-28 |
| US20160082145A1 (en) | 2016-03-24 |
| HUE034649T2 (hu) | 2018-02-28 |
| JP2016510315A (ja) | 2016-04-07 |
| AU2013366544A1 (en) | 2015-07-09 |
| SI2934612T1 (sl) | 2017-08-31 |
| PL2934612T3 (pl) | 2017-08-31 |
| EP2934612A1 (en) | 2015-10-28 |
| CN104955493A (zh) | 2015-09-30 |
| WO2014096354A1 (en) | 2014-06-26 |
| DK2934612T3 (en) | 2017-06-26 |
| PT2934612T (pt) | 2017-06-26 |
| LT2934612T (lt) | 2017-07-25 |
| JP6518591B2 (ja) | 2019-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ592509A (en) | HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same | |
| NZ621868A (en) | Growth hormone polypeptides and methods of making and using same | |
| TN2009000124A1 (en) | Injectable depot composition and its process of preparation | |
| RS54707B1 (en) | TREATMENT OF CROWN LAKVINIMOD DISEASE | |
| RS54551B1 (en) | NEUROPROTECTION IN DEMYELINING DISEASES | |
| IL207468A (en) | HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections | |
| HRP20240168T1 (hr) | Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije | |
| RU2600440C3 (ru) | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты | |
| WO2010100506A3 (en) | Delivery system with scaffolds | |
| BRPI0906104A2 (pt) | "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto" | |
| MX2010004613A (es) | Composicion topica. | |
| AR061929A1 (es) | Acidos nucleicos de union al factor derivado de celulas estomales sdf-1 | |
| MX2010002557A (es) | Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo. | |
| EA200700976A1 (ru) | Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой | |
| ATE413865T1 (de) | Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür | |
| HRP20170880T1 (hr) | Sastavi za brtvljenje | |
| AR064720A1 (es) | Microvesiculas derivadas de levadura recombinante con actividades hemostaticas y usos de las mismas | |
| BR112013004436A2 (pt) | composições e usos de materiais com atividade microbicida alta e toxicidade baixa | |
| NZ701205A (en) | Optimised subcutaneous therapeutic agents | |
| EA200701228A1 (ru) | Стабильные композиции фенофибрата с эфирами жирных кислот | |
| TNSN08506A1 (en) | Substituted carboxamides | |
| WO2010132690A3 (en) | Compositions and methods for promoting tissue repair and wound healing | |
| HRP20170794T1 (hr) | Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a | |
| NO20051261L (no) | Morfin-6-glukuronidsalt | |
| FR2963237B1 (fr) | Nouvelle composition pharmaceutique utile pour prevenir ou traiter l'hypotension arterielle peroperatoire chez l'etre humain |